| |
Custom Synthesis
BASF produces customized active ingredients and advanced intermediates exclusively and in complete confidence on behalf of pharmaceutical companies. BASF’s experts offer support through the drug lifecycle - from kilo laboratory to commercial production, from the early clinical phase to market launch and even when the drug becomes generic.
In 2005 BASF acquired the Swiss fine chemicals company Orgamol, which can boast over fifty years of experience and success in the field of exclusive synthesis. Thanks to this increase in know-how and further production facilities, BASF has come to offer even more comprehensive custom synthesis services. We are now one of the leading companies in this sector.
|
We bring the right assets, the right chemistry and the right experience together.
BASF now has a U.S.-based Custom Synthesis team to serve the needs of pharmaceutical companies in North America.
Contact us today to learn how we can help you accelerate new pharmaceuticals
to market:
By phone: +1-973-245-6384
By e-mail: customsynthesis@basf.com |
|
|
 |
News |
| |
|
June 19, 2008:
Leading the way in respect of quality standards for pharmaceutical excipients
(english, deutsch) May 16, 2008:
Pharmaceutical excipient for instant-release tablet coatings approved in USA
(english, deutsch) April 30, 2008:
BASF sells its Shreveport site and related contract manufacturing business to Dr. Reddy's Laboratories
(english, deutsch)
|
|
 |
Product Search |
 |
|
|